- Home
- SEMR vs DNTH Comparison
SEMR vs DNTH Comparison
Compare SEMR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- DNTH
- Stock Information
- Founded
- SEMR 2008
- DNTH 2015
- Country
- SEMR United States
- DNTH United States
- Employees
- SEMR N/A
- DNTH N/A
- Industry
- SEMR EDP Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- DNTH Health Care
- Exchange
- SEMR Nasdaq
- DNTH Nasdaq
- Market Cap
- SEMR 1.2B
- DNTH 1.0B
- IPO Year
- SEMR 2021
- DNTH N/A
- Fundamental
- Price
- SEMR $7.53
- DNTH $36.29
- Analyst Decision
- SEMR Buy
- DNTH Strong Buy
- Analyst Count
- SEMR 8
- DNTH 8
- Target Price
- SEMR $14.88
- DNTH $60.67
- AVG Volume (30 Days)
- SEMR 1.2M
- DNTH 894.0K
- Earning Date
- SEMR 11-06-2025
- DNTH 11-06-2025
- Dividend Yield
- SEMR N/A
- DNTH N/A
- EPS Growth
- SEMR N/A
- DNTH N/A
- EPS
- SEMR N/A
- DNTH N/A
- Revenue
- SEMR $413,962,000.00
- DNTH $4,854,000.00
- Revenue This Year
- SEMR $20.28
- DNTH N/A
- Revenue Next Year
- SEMR $16.41
- DNTH N/A
- P/E Ratio
- SEMR N/A
- DNTH N/A
- Revenue Growth
- SEMR 22.16
- DNTH 17.87
- 52 Week Low
- SEMR $7.01
- DNTH $13.37
- 52 Week High
- SEMR $18.74
- DNTH $38.59
- Technical
- Relative Strength Index (RSI)
- SEMR 42.14
- DNTH 81.38
- Support Level
- SEMR $7.32
- DNTH $22.81
- Resistance Level
- SEMR $7.90
- DNTH $24.81
- Average True Range (ATR)
- SEMR 0.22
- DNTH 2.67
- MACD
- SEMR 0.02
- DNTH 1.43
- Stochastic Oscillator
- SEMR 25.17
- DNTH 88.21
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.